Clinical Trials Logo

Clinical Trial Summary

This study is a randomized, double-blind, placebo-controlled, dose-ranging, parallel, multi-center, phase II study to evaluate the efficacy and safety of MT921 in subjects with moderate to severe submental fat.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04144049
Study type Interventional
Source Medy-Tox
Contact
Status Completed
Phase Phase 2
Start date September 10, 2019
Completion date April 23, 2020

See also
  Status Clinical Trial Phase
Completed NCT05476679 - Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events Phase 1/Phase 2
Active, not recruiting NCT05154955 - A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat Phase 2
Completed NCT04258761 - A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin") Phase 2
Recruiting NCT03946592 - Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat Phase 3
Completed NCT05763160 - An Open-label Study That Will Test a Second Treatment Session of RZL-012. Phase 2
Completed NCT04867434 - Efficacy and Safety of RZL-012 on Submental Fat Reduction Phase 2
Completed NCT05466448 - An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects. Phase 1/Phase 2
Completed NCT04086823 - A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers. Phase 2
Completed NCT02159729 - Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 Phase 2
Completed NCT05195112 - Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat Phase 3
Completed NCT03005717 - Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat Phase 2
Completed NCT02163902 - Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 Phase 3
Completed NCT05476094 - Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects Phase 1